ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

Julie R. Brahmer, MD
Published: Thursday, Jun 07, 2012

Julie R. Brahmer, MD, associate professor of oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, discusses a phase I clinical trial that investigated the experimental agent BMS-936558, a targeted immunotherapy agent that blocks the programmed death-1 (PD-1) receptor that is expressed by activated T cells, in multiple tumor types.

Brahmer explains this trial is the second to investigate this antibody in clinical trials for humans. On the trial, patients received BMS-936558 once every two weeks in an eight-week cycle for up to two years. The trial enrolled 296 patents with advanced melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma (RCC), and prostate cancer.

The dose escalation portion of the trial provided doses between 0.1 to 10.0 mg/kg but did not find a maximum tolerated dose because all dose sizes were well tolerated. BMS-936558 was generally well tolerated and all side effects of the agent were similar to other immunotherapies and included pneumonitis, hypophysitis, hepatitis, colitis, and thyroiditis.

Activity was noted prominently in patients with melanoma (28% of patients), RCC (27%), and NSCLC (18%). Brahmer notes that some patients demonstrated a prolonged response to the therapy that lasted not only for the two years they received the agent but also an additional year after the therapy was stopped.

Julie R. Brahmer, MD, associate professor of oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, discusses a phase I clinical trial that investigated the experimental agent BMS-936558, a targeted immunotherapy agent that blocks the programmed death-1 (PD-1) receptor that is expressed by activated T cells, in multiple tumor types.

Brahmer explains this trial is the second to investigate this antibody in clinical trials for humans. On the trial, patients received BMS-936558 once every two weeks in an eight-week cycle for up to two years. The trial enrolled 296 patents with advanced melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma (RCC), and prostate cancer.

The dose escalation portion of the trial provided doses between 0.1 to 10.0 mg/kg but did not find a maximum tolerated dose because all dose sizes were well tolerated. BMS-936558 was generally well tolerated and all side effects of the agent were similar to other immunotherapies and included pneumonitis, hypophysitis, hepatitis, colitis, and thyroiditis.

Activity was noted prominently in patients with melanoma (28% of patients), RCC (27%), and NSCLC (18%). Brahmer notes that some patients demonstrated a prolonged response to the therapy that lasted not only for the two years they received the agent but also an additional year after the therapy was stopped.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x